Hutchison China Meditech Limited Blocklisting Six Monthly Return (7017L)
31 December 2018 - 6:00PM
UK Regulatory
TIDMHCM
RNS Number : 7017L
Hutchison China Meditech Limited
31 December 2018
Blocklisting Six Monthly Return
London: Monday, December 31, 2018: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following
blocklisting six monthly return:
1. Name of applicant: Hutchison China MediTech Limited
2. Name of scheme: (a) Share Option Scheme conditionally adopted
by Hutchison China MediTech Limited
in 2005 ("2005 HCML Share Option Scheme")
(b) Share Option Scheme conditionally adopted
by Hutchison China MediTech Limited
in 2015 ("2015 HCML Share Option Scheme")
3. Period of return: From June 29, 2018 to December 28, 2018
4. Balance under scheme (a) 2005 HCML Share Option Scheme: 219,353
from previous return: ordinary shares of US$1 each
(b) 2015 HCML Share Option Scheme: 2,425,597
ordinary shares of US$1 each
5. The amount by which (a) 2005 HCML Share Option Scheme: Nil
the block scheme has
been increased, if
the scheme has been
increased since the
date of the last return:
(b) 2015 HCML Share Option Scheme: Nil
6. Number of securities (a) 2005 HCML Share Option Scheme: 12,562
issued/allotted under ordinary shares of US$1 each
scheme during period:
(b) 2015 HCML Share Option Scheme: 112,500
ordinary shares of US$1 each
7. Balance under scheme (a) 2005 HCML Share Option Scheme: 206,791
not yet issued/allotted ordinary shares of US$1 each
at end of the period:
(b) 2015 HCML Share Option Scheme: 2,313,097
ordinary shares of US$1 each
8. Number and class of (i) 2,560,606 ordinary shares of US$1 each
securities originally admitted on June 26, 2007
listed and the date
of admission:
(ii) 1,000,000 ordinary shares of US$1 each
admitted on June 20, 2016
(iii) 1,425,597 ordinary shares of US$1 each
admitted on April 27, 2018
9. Total number of securities 66,657,745 ordinary shares of US$1 each
in issue at the end
of the period:
Name of contact: Christian Hogg
Address of contact: Level 18, The Metropolis Tower, 10 Metropolis
Drive, Hung Hom, Kowloon, Hong Kong
Telephone number of contact: +852 2121 8200
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical
company which researches, develops, manufactures and markets
pharmaceutical products. Its Innovation Platform, Hutchison
MediPharma, has about 400 scientists and staff focusing on
discovering, developing and commercializing targeted therapeutics
in oncology and autoimmune diseases. It has a portfolio of eight
cancer drug candidates currently in clinical studies around the
world. Chi-Med's Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products,
covering an extensive network of hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and
the Nasdaq Global Select Market, Chi-Med is headquartered in Hong
Kong and majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development +852 2121 8200
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
Zhou Yi, +852 9783 6894 (Mobile)
Brunswick yzhou@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 136 7179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BLRUWSKRWBAUURA
(END) Dow Jones Newswires
December 31, 2018 02:00 ET (07:00 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024